NCT03367819 - Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions

Prostate CancerNon-small Cell Lung Cancer

Interventions

DRUG

Isatuximab SAR650984

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

DRUG

Cemiplimab REGN2810

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

Trial Locations (16)

704

Investigational Site Number 1580002, Tainan City

10043

Investigational Site Number 3800001, Orbassano

20089

Investigational Site Number 3800003, Rozzano

30322

Investigational Site Number 8400007, Atlanta

33076

Investigational Site Number 2500002, Bordeaux

35128

Investigational Site Number 3800004, Padua

35249

Investigational Site Number 8400003, Birmingham

37134

Investigational Site Number 3800005, Verona

37203

Investigational Site Number 8400005, Nashville

77030

Investigational Site Number 8400004, Houston

80131

Investigational Site Number 3800006, Napoli

94800

Investigational Site Number 2500001, Villejuif

07601

Investigational Site Number 8400002, Hackensack

Unknown

Investigational Site Number 1580001, Taipei

SM2 5PT

Investigational Site Number 8260001, Sutton

NE7 7DN

Investigational Site Number 8260002, Newcastle upon Tyne